Open this publication in new window or tab >>Karlstad University, Sweden.
Vrije Universiteit Amsterdam, The Netherlands.
DTU Technical University of Denmark, Denmark.
Muséum national d'Histoire naturelle, France.
Erasmus Medical Centre, The Netherlands.
Muséum national d'Histoire naturelle, France.
Charitė Universitätsmedizin Berlin, Germany.
Vrije Universiteit Amsterdam, Netherlands.
Charitė Universitätsmedizin Berlin, Germany.
Charitė Universitätsmedizin Berlin, Germany.
Erasmus Medical Centre, The Netherlands.
RISE Research Institutes of Sweden, Bioeconomy and Health, Chemical Process and Pharmaceutical Development.
Brunel University London, UK.
Erasmus Medical Centre, Netherlands.
Charité Universitätsmedizin Berlin, Germany; Berlin Institute of Health, Germany.
DTU Technical University of Denmark, Denmark.
Laboratoire Watchfrog, France.
Erasmus Medical Centre, The Netherlands.
RISE Research Institutes of Sweden, Bioeconomy and Health, Chemical Process and Pharmaceutical Development.
DTU Technical University of Denmark, Denmark.
Muséum national d'Histoire naturelle, France.
Charitė Universitätsmedizin Berlin, Germany.
Brunel University London, UK.
Charité Universitätsmedizin Berlin, Germany; Berlin Institute of Health, Germany.
DTU Technical University of Denmark, Denmark.
Vrije Universiteit Amsterdam, Netherlands.
DTU Technical University of Denmark, Denmark.
Orebro University, Sweden.
Show others...
2020 (English)In: International Journal of Molecular Sciences, ISSN 1661-6596, E-ISSN 1422-0067, Vol. 21, no 9, article id E3123Article in journal (Refereed) Published
Abstract [en]
The test methods that currently exist for the identification of thyroid hormone system-disrupting chemicals are woefully inadequate. There are currently no internationally validated in vitro assays, and test methods that can capture the consequences of diminished or enhanced thyroid hormone action on the developing brain are missing entirely. These gaps put the public at risk and risk assessors in a difficult position. Decisions about the status of chemicals as thyroid hormone system disruptors currently are based on inadequate toxicity data. The ATHENA project (Assays for the identification of Thyroid Hormone axis-disrupting chemicals: Elaborating Novel Assessment strategies) has been conceived to address these gaps. The project will develop new test methods for the disruption of thyroid hormone transport across biological barriers such as the blood-brain and blood-placenta barriers. It will also devise methods for the disruption of the downstream effects on the brain. ATHENA will deliver a testing strategy based on those elements of the thyroid hormone system that, when disrupted, could have the greatest impact on diminished or enhanced thyroid hormone action and therefore should be targeted through effective testing. To further enhance the impact of the ATHENA test method developments, the project will develop concepts for better international collaboration and development in the area of thyroid hormone system disruptor identification and regulation.
Keywords
brain development, endocrine disruptors, risk assessment, test method development, test method validation, thyroid hormone system
National Category
Natural Sciences
Identifiers
urn:nbn:se:ri:diva-45043 (URN)10.3390/ijms21093123 (DOI)32354186 (PubMedID)2-s2.0-85084009621 (Scopus ID)
2020-05-292020-05-292022-02-10Bibliographically approved